These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16859593)

  • 1. A case of arthritis and vasculitis associated with the refractory anemia with excess of blasts syndrome resistant to glucocorticoid treatment that responded favorably to TNF-alpha blockade.
    Pipitone N; Masini L; Salvarani C
    Clin Exp Rheumatol; 2006; 24(2 Suppl 41):S31-4. PubMed ID: 16859593
    [No Abstract]   [Full Text] [Related]  

  • 2. TNF-alpha inhibitors offer hope to RA patients.
    Wimett L
    Nurse Pract; 2003 Oct; 28(10):40-8. PubMed ID: 14560130
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
    Wallenius M; Rødevand E; Skomsvoll JF
    Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1664-6. PubMed ID: 15976836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of aseptic abscesses syndrome treated with corticosteroids and TNF-alpha blockade.
    Ito T; Sato N; Yamazaki H; Koike T; Emura I; Saeki T
    Mod Rheumatol; 2013 Jan; 23(1):195-9. PubMed ID: 22526827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-TNF alpha agents in vasculitis].
    Solans Laqué R; Bosch Gil JA
    Med Clin (Barc); 2008 Feb; 130(3):93-4. PubMed ID: 18261379
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
    Foeldvari I; Nielsen S; Kümmerle-Deschner J; Espada G; Horneff G; Bica B; Olivieri AN; Wierk A; Saurenmann RK
    J Rheumatol; 2007 May; 34(5):1146-50. PubMed ID: 17343318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF involvement and anti-TNF therapy of reactive and unclassified arthritis.
    Meador R; Hsia E; Kitumnuaypong T; Schumacher HR
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S130-4. PubMed ID: 12463463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA; Agudo M
    Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of sarcoidosis during etanercept therapy.
    González-López MA; Blanco R; González-Vela MC; Fernández-Llaca H; Rodríguez-Valverde V
    Arthritis Rheum; 2006 Oct; 55(5):817-20. PubMed ID: 17013853
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis.
    Bosello S; De Santis M; Tolusso B; Zoli A; Ferraccioli G
    Ann Intern Med; 2005 Dec; 143(12):918-20. PubMed ID: 16365478
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade.
    Arbach O; Gross WL; Gause A
    Immunobiology; 2002 Dec; 206(5):496-501. PubMed ID: 12607724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Are anti-TNFAb indicated in systemic necrotizing vasculitides?].
    Guillevin L
    Rev Med Interne; 2005 Oct; 26(10):769-70. PubMed ID: 16039017
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiating the efficacy of tumor necrosis factor inhibitors.
    Haraoui B
    J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases.
    Fujikawa K; Kawakami A; Hayashi T; Iwamoto N; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Ida H; Origuchi T; Eguchi K
    Mod Rheumatol; 2010 Feb; 20(1):86-9. PubMed ID: 19812889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists.
    Gottlieb GS; Lesser CF; Holmes KK; Wald A
    Clin Infect Dis; 2003 Sep; 37(6):838-40. PubMed ID: 12955647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
    Asahina A; Ishii N; Tohma S
    J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
    [No Abstract]   [Full Text] [Related]  

  • 19. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases.
    Kalden JR
    Arthritis Res; 2002; 4 Suppl 2(Suppl 2):S34-40. PubMed ID: 12110156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.